pharmaceutical investing Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
pharmaceutical investing Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
pharmaceutical investing AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® Subcutaneous Induction in Patients with Crohn's Disease
pharmaceutical investing ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart maintains high levels of viral suppression in long-acting HIV treatment regimen
pharmaceutical investing CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
pharmaceutical investing Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
pharmaceutical investing U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
pharmaceutical investing Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
pharmaceutical investing AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
pharmaceutical investing Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
pharmaceutical investing Aquestive Therapeutics to Present New Clinical Data on Anaphylm Sublingual Film at the 2026 AAAAI Annual Meeting
